Glenn Tillitson, PhD, FIDSA, FRSM,, FCCP, FISC
Doctor Glenn Tillitson has over 30 years in experience in global infectious disease and with a focus in anti-infective drug development and medical educational and medical affairs. Dr. Tillitson has written many publications in the various aspects of ID (>150 papers on PubMed with a further >40 not cited). Demonstrated capabilities in broad-ranging educational initiatives aimed at improving patient health. Dr. Tillitson has published multiple publications and an e-book on C difficile. Recently he has been active in developing new products for Clostridium difficile, MRSA and MDR Gram-negative infections. Built and led a medical affairs team to prepare for the approval and launch of a fourth-generation macrolide for use in pneumonia. Most recently played a role in the approval of cefiderocol ,a novel siderophore cephalosporin, in the USA.
